CTLA4 and neoplasm: These strategies include combining γδT cell therapy with immune checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4), engineering γδT cells to resist TME-induced exhaustion, and utilizing approaches such as local tumor irradiation or metabolic reprogramming to enhance γδT cell recognition and infiltration in solid tumor settings.